Spatiotemporal Ultrasound‐Driven Bioorthogonal Catalytic Therapy. Issue 7 (18th December 2022)

• Record Type: Journal Article
• Authors: Xia, Lili; Chen, Meng; Dong, Caihong; Liu, Feipeng; Huang, Hui; Feng, Wei; Chen, Yu
• Is Part Of: Advanced materials. Volume 35:Issue 7(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-18
• Subjects: bioorthogonal chemistry -- catalytic therapy -- spatiotemporal control -- theranostics -- ultrasmall copper nanocomplexes; Materials -- Periodicals; Chemical vapor deposition -- Periodicals; 620.11
• DOI: 10.1002/adma.202209179
• Languages: English
• ISSNs: 0935-9648

Abstract

Abstract: Bioorthogonal chemistry, referring to the rapid and selective synthesis of imaging and/or therapeutic molecules in live animals via transition metal‐mediated non‐natural chemical transformation without disrupting endogenous reactions, has greatly expanded the tools and techniques for biomedicine. However, owing to safety concerns associated with metal toxicity, selectivity, sensitivity and stability, efficient bioorthogonal reactions that can be reliably executed in complex biological environments remain challenging. In this study, an intelligent, versatile bioorthogonal catalyst based on ultrasmall poly(acrylic acid)‐modified copper nanocomplexes (Cu@PAA NCs) to achieve high spatiotemporal catalytic efficacy is established. The catalytic activity of the Cu@PAA NCs can be reversibly regulated via valence state interconversion between Cu(II) and Cu(I) under exogenous ultrasound irradiation, promoting off‐target prodrug activation in lesion sites through the Cu(I)‐catalyzed azide–alkyne cycloaddition reaction. Moreover, ultrasound‐triggered electron–hole separation endows the Cu@PAA NCs with robust sonosensitizing ability for sonodynamic therapy. Furthermore, the Cu@PAA NCs exhibit enhanced contrast in magnetic resonance and photoacoustic imaging. Notably, the renal‐clearable Cu@PAA NCs exhibit intrinsically benign biocompatibility. This spatiotemporally ultrasound‐mediated bioorthogonal catalysis not only expands the repertoire of in situ therapeutic agents but also provides a new avenue for disease theranostics. Abstract : The development of bioorthogonal catalysis is highly challenging owing to safety concerns of metal toxicity and low spatiotemporal regulation in vivo. Here, an intelligent Cu@PAA NCs catalyst is developed, the catalytic activity of which can be precisely regulated via valence state transformation between Cu(II) and Cu(I) under ultrasound irradiation, promoting off‐target prodrug activation at lesion sites and generating ROS.